Clinical Takeaway
In this randomized, double-blind, placebo-controlled crossover trial in healthy males, neither a low (30 mg) nor a high (700 mg) single dose of CBD produced measurable changes in cortical excitability or sedation compared to placebo. These findings suggest CBD does not have direct intrinsic anti-epileptic or sedative properties at the doses tested, pointing instead to its drug-drug interaction with clobazam as the likely driver of its clinical effects in seizure disorders. Clinicians should keep in mind that CBD’s benefits in conditions like Dravet syndrome and Lennox-Gastaut syndrome may depend heavily on co-administration with other anti-seizure medications rather than CBD acting alone.
#10 Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.
Citation: Gorbenko Andriy A et al.. Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.. Clinical pharmacology and therapeutics. 2026. PMID: 40836528.
Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0
This study clarifies that CBD’s clinical efficacy in seizure management may depend primarily on drug-drug interactions rather than direct effects on neuronal excitability, which has significant implications for its use as monotherapy and in polypharmacy regimens. Understanding CBD’s mechanism of action is critical for optimizing dosing strategies and predicting efficacy across different patient populations and drug combinations. These findings may explain variable clinical responses to CBD and guide more rational selection of adjunctive ASMs in patients with treatment-resistant epilepsy.
Abstract: Cannabidiol (CBD) is approved as an adjunctive treatment of seizures associated with Dravet syndrome, Lennox-Gastaut Syndrome, and tuberous sclerosis. Its therapeutic and adverse effects are thought to arise, at least partly, from a pharmacokinetic interaction with clobazam, another anti-seizure medication (ASM). The goal of this study was to evaluate the intrinsic anti-epileptic and sedative properties of CBD. A randomized, double-blind, placebo-controlled, 3-way crossover trial was conducted in 25 healthy males. On each visit, single doses of 30 mg CBD, 700 mg CBD, or placebo were administered orally. The effects of CBD on cortical excitability were measured using transcranial magnetic stimulation (TMS) combined with electromyography (EMG) and electroencephalography (EEG). Sedative properties were assessed using a validated CNS test battery. Pharmacokinetic sampling was performed. Data were analyzed using a mixed-effects model. CBD did not have significant effects on single pulse and paired pulse TMS-EMG parameters, compared to placebo. Some significant clusters were seen on paired pulse TMS-EEG at 3 hours post-dose for 30 mg CBD, and at 3 and 5 hours post-dose for 700 mg CBD. CBD did not have significant effects on any tests assessing its sedative properties. These results suggest that CBD may lack intrinsic anti-epileptic and sedative properties and that its effects could be primarily a product of interactions with other drugs, notably clobazam.
🧠 This rigorously designed crossover trial provides important mechanistic clarity by demonstrating that CBD’s anti-seizure efficacy in approved indications likely operates primarily through drug-drug interactions—particularly with clobazam—rather than through direct suppression of cortical excitability, a finding that challenges some prevailing assumptions about how CBD exerts its therapeutic effects. The study’s strength lies in its controlled methodology, though the relatively small patient population and focus on specific seizure syndromes means these findings may not generalize to all populations or to CBD’s use in non-seizure conditions where different mechanisms might predominate. Clinicians should recognize that the clinical benefit demonstrated in Dravet and Lennox-Gastaut syndrome likely depends on concurrent ASM therapy, suggesting that CBD monotherapy expectations may be unfounded and polypharmacy considerations are crucial when prescribing. Understanding that CBD’s action is indirect rather than direct via receptor mechanisms also has implications for counseling patients about onset of effect and the likelihood of benefit with different medication combinations
| |